Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Showcases Maralixibat Transplant-Free Survival Data for PFIC and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

Click to view original post